Encord has successfully helped customers extract and use meaningful business context from unstructured data in 2024, enabling them to improve business operations, save lives, delight users and customers, and make GenAI models work better for businesses with richer data. The company achieved groundbreaking research in GenAI with Synthesia and Flawless AI, onboarded AI innovators, released game-changing product enhancements including support for SAM 2 within 48 hours of its public release, closed a $32M Series B funding round, and opened a new San Francisco office to build and scale global GTM functions. Encord's computer vision and medical AI data platform evolved to enable teams to discover, manage, curate, and annotate petabyte-scale document, text, and audio datasets, introducing a multimodal annotation interface facilitating reinforced learning from human feedback workflows and multi-file analysis in one view. The company also released Encord Data Agents, which allow teams to integrate AI models into their data workflows in a highly customizable way, saving hours of annotation time and boosting label throughput. Additionally, Encord's audio data curation and annotation capability is designed for effective annotation workflows for AI teams working with any type and size of audio dataset, while its document and text annotation tool provides comprehensive capabilities for labeling large-scale datasets.